688136 科兴制药
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)1.5511.931-11.081-4.8565.157
总资产报酬率 ROA (%)0.8051.017-6.143-3.0133.713
投入资产回报率 ROIC (%)0.8811.115-6.734-3.3414.125

边际利润分析
销售毛利率 (%)67.87668.68970.79175.36579.410
营业利润率 (%)9.6504.492-20.351-10.5307.626
息税前利润/营业总收入 (%)11.0436.948-18.179-9.4347.832
净利润/营业总收入 (%)7.0291.923-15.527-7.0547.506

收益指标分析
经营活动净收益/利润总额(%)95.257109.898104.758100.52938.389
价值变动净收益/利润总额(%)11.965-34.906-2.6022.28259.240
营业外收支净额/利润总额(%)-7.338-11.0681.4760.363-2.483

偿债能力分析
流动比率 (X)1.5011.4531.6922.6172.420
速动比率 (X)1.3581.2931.4062.2312.135
资产负债率 (%)47.77548.16246.19842.93832.461
带息债务/全部投入资本 (%)42.48042.19740.12135.78622.333
股东权益/带息债务 (%)133.590134.890146.148175.534338.666
股东权益/负债合计 (%)109.076107.349116.120133.080208.059
利息保障倍数 (X)5.3792.393-7.340-8.31820.022

营运能力分析
应收账款周转天数 (天)126.40195.92887.48092.14496.756
存货周转天数 (天)106.191136.135195.562211.192194.229